GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) » Definitions » ROE %
中文

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) ROE % : 12.20% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized net income for the quarter that ended in Dec. 2023 was E£212 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was E£1,734 Mil. Therefore, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized ROE % for the quarter that ended in Dec. 2023 was 12.20%.

The historical rank and industry rank for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE % or its related term are showing as below:

CAI:RMDA' s ROE % Range Over the Past 10 Years
Min: 9.94   Med: 14.62   Max: 27.31
Current: 14.93

During the past 6 years, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's highest ROE % was 27.31%. The lowest was 9.94%. And the median was 14.62%.

CAI:RMDA's ROE % is ranked better than
81.8% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.42 vs CAI:RMDA: 14.93

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ROE % Historical Data

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ROE % Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial 10.66 9.94 14.30 17.14 14.93

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.57 17.11 12.23 18.33 12.20

Competitive Comparison of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE % distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE % falls into.



Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ROE % Calculation

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=244.859/( (1518.587+1762.563)/ 2 )
=244.859/1640.575
=14.93 %

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=211.584/( (1705.845+1762.563)/ 2 )
=211.584/1734.204
=12.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=211.584/1734.204
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(211.584 / 2136.768)*(2136.768 / 3244.0885)*(3244.0885 / 1734.204)
=Net Margin %*Asset Turnover*Equity Multiplier
=9.9 %*0.6587*1.8706
=ROA %*Equity Multiplier
=6.52 %*1.8706
=12.20 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=211.584/1734.204
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (211.584 / 292.524) * (292.524 / 455.84) * (455.84 / 2136.768) * (2136.768 / 3244.0885) * (3244.0885 / 1734.204)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7233 * 0.6417 * 21.33 % * 0.6587 * 1.8706
=12.20 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ROE % Related Terms

Thank you for viewing the detailed overview of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. It is engaged in the manufacture and sale of branded generic pharmaceutical products nutraceuticals, cosmeceuticals, food supplements, medical devices, and veterinary products. The firm is engaged in therapeutic areas namely systemic anti-infectives, alimentary tract and metabolism, genitourinary system and sex hormones, cardiovascular system, nervous system, and blood and blood-forming organs.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Headlines

No Headlines